Documents Indicate Glaxo Hid Test Data on Risks of Avandia

The New York Times (7/13, A1, Harris) reported that, according to recently obtain documents, SmithKline Beecham (the precurser to GlaxoSmithKline) spent years attempting to cover up a study that found that Avandia (rosiglitazone) was “riskier to the heart.” In an email message dated March 29, 2001, Dr. Martin I. Freed wrote, “Per Sr. Mgmt request, these data should not see the light of day to anyone outside of GSK.”

The Wall Street Journal (7/13, Mundy) reported that Dr. Rosemary Johann-Liang (a former FDA official) said that there were early reports written by company researchers that noted scientists’ concerns about heart risks of taking Avandia.